May 21, 2025 – We’re pleased to announce that Frier Levitt Partner Arielle Miliambro was quoted in Axios regarding the evolving role of compounding pharmacies in the distribution of GLP‑1 therapies, following the Food and Drug Administration’s move to enforce a ban on copycat GLP‑1 drugs effective May 22, 2025.
In the Axios article, “How compounders plan to continue making GLP‑1s,” Arielle provides insights into how some pharmacies and telemedicine firms are interpreting current FDA regulations. She underscores the argument that the FDA still allows custom-compounded formulations tailored to individual patient needs, even as brand-name manufacturers prepare to challenge this approach Axios.
This timely coverage reflects Frier Levitt’s commitment to staying at the forefront of legal and regulatory shifts in the healthcare and pharmacy industries, especially those impacting compounding pharmacies.
You can read the full Axios article on this critical issue here.
